A dose-finding study of once-daily oral
โ
Ching-Lung Lai; Seng Gee Lim; Nathaniel A. Brown; Xiao-Jian Zhou; Deborah M. Llo
๐
Article
๐
2004
๐
John Wiley and Sons
๐
English
โ 305 KB
๐ 1 views
Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa